Acquisition of Southern Cross Diagnostics

AI SummaryClose X

Novacyt S.A. has conditionally agreed to acquire Southern Cross Diagnostics Pty Ltd for an initial cash consideration of AUD$8.5m (approximately £4.4m), a move expected to be immediately earnings and revenue accretive. Southern Cross Diagnostics, a profitable Australian distributor, reported revenues of circa £6.7m and a net profit of circa £0.8m for the year ended June 2025, and its acquisition provides Novacyt direct access to the growing Australian diagnostic market. The transaction also includes potential contingent consideration of up to AUD$16.5m based on future financial performance, and the founder of Southern Cross Diagnostics will invest up to AUD$0.8m in Novacyt shares.

Disclaimer*

UK 100

Latest directors dealings